血栓通软胶囊联合苯磺酸氨氯地平治疗高血压合并脑梗死的疗效及对血压、血液流变学的影响

Therapeutic effect of Xueshuantong soft capsules combined with amlodipine besylate on hypertension complicated with cerebral infarction and its impact on blood pressure,hemorheology

目的评价血栓通软胶囊联合苯磺酸氨氯地平治疗高血压合并脑梗死的疗效及对血压、血液流变学的影响。方法回顾性选取2018年6月至2023年6月铜川市人民医院收治的82例高血压合并脑梗死患者作为研究对象。根据治疗方法不同分为对照组和联合组,各41例。对照组给予口服苯磺酸氨氯地平治疗,联合组给予口服苯磺酸氨氯地平+血栓通软胶囊治疗。两组均连续治疗14 d。比较两组患者的临床疗效,并比较两组患者治疗前,治疗后7、14 d的美国国立卫生研究院卒中量表(NIHSS)评分和改良Rankin评分量表(mRS)评分、血压、血液流变学[血浆黏度(PV)、全血低切黏度(LBV)和全血高切黏度(HBV)]及不良反应。结果联合组总有效率为95.12%,显著高于对照组(73.17%),差异有统计学意义(P<0.05)。治疗后7、14 d,联合组NIHSS评分分别为(13.75±2.51)、(8.51±2.17)分,均低于对照组[(15.62±2.97)分、(10.46±2.34)分],联合组mRS评分分别为(3.02±0.35)、(2.78±0.29)分,均显著低于对照组[(3.42±0.37)、(3.01±0.32)分],差异均有统计学意义(P<0.05)。联合组治疗后14 d的收缩压和舒张压分别为(124.43±6.26)、(81.48±3.43)mmHg,均显著低于对照组[(135.86±7.10)、(90.97±5.58)mmHg],差异均有统计学意义(P<0.05)。联合组治疗后14 d的PV、HBV、LBV分别为(1.35±0.24)、(5.16±0.61)、(9.20±1.49)mPa·s,均显著低于对照组[(2.05±0.32)、(6.94±0.72)、(11.09±1.84)mPa·s],差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论血栓通胶囊联合苯磺酸氨氯地平治疗可提高高血压合并脑梗死患者的疗效,改善神经功能,改善血压、血液流变学,且安全性好。

Objective To evaluate the efficacy of Xueshuantong soft capsules combined with amlodipine besylate in the treatment of hypertension complicated with cerebral infarction and its impact on blood pressure,hemorheology.Methods Eighty-two patients with hypertension complicated with cerebral infarction admitted to Tongchuan People's Hospital from June 2018 to June 2023 were retrospectively selected as the study subjects.They were divided into the control group and the combination group based on different treatment methods,with 41 cases in each group.The control group was treated with oral amlodipine benzenesulfonate,and the combined group was treated with oral amlodipine benzenesulfonate+Xueshuantong soft capsules.Both groups were treated continuously for 14 d.The clinical efficacy of two groups of patients was compared.The National Institutes of Health Stroke Scale(NIHSS)and Modified Rankin Scale(mRS)scores before treatment,after 7 days of treatment,and after 14 days of treatment,blood pressure,hemorheology[plasma viscosity(PV),whole blood low shear viscosity(LBV),and whole blood high shear viscosity(HBV)]before treatment,after 7 days of treatment,and adverse reactions were compared.Results The total effective rate of the combined group was 95.12%,which was significantly higher than that of the control group(73.17%),and the difference was statistically significant(P<0.05).After 7 and 14 days of treatment,the NIHSS scores of the combination group were(13.75±2.51)and(8.51±2.17)points,respectively,which were lower than those of the control group[(15.62±2.97)points and(10.46±2.34)points],the mRS scores of the combination group were(3.02±0.35)and(2.78±0.29)points,respectively,which were significantly lower than those of the control group[(3.42±0.37)and(3.01±0.32)points],and the differences were statistically significant(P<0.05).After 14 days of treatment,the systolic and diastolic blood pressure in the combination group were(124.43±6.26)and(81.48±3.43)mmHg,respectively,which were significantly lower than those in the control group[(135.86±7.10)and(90.97±5.58)mmHg],and the differences were statistically significant(P<0.05).After 14 days of treatment,the PV,HBV,and LBV of the combination group were(1.35±0.24),(5.16±0.61),and(9.20±1.49)mPa·s,respectively,which were significantly lower than those of the control group[(2.05±0.32),(6.94±0.72),and(11.09±1.84)mPa·s],and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of Xueshuantong soft capsules and amlodipine besylate can improve the therapeutic effect of hypertensive patients with cerebral infarction,improve neurological function,improve blood pressure and hemorheology,and have good safety.